Detail akcie Intensity Therap Rg online

Business Summary: Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Intensity Therapeutics Inc revenues was not reported. Net loss decreased 35% to $8.6M. Lower net loss reflects Research and development costs - decrease of 40% to $3.8M (expense), General and administrative costs - Balan decrease of 28% to $1.9M (expense), Labor & Related Expenses in R&D decrease of 31% to $925K (expense).